Company intelligence / Profile preview
Parvus Therapeutics
South San Francisco, California, United Statesparvustx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Lead candidate PVT201 is in Phase 1/2 clinical trial in Australia for liver autoimmune disease. Second candidate PVT401 is in development for inflammatory bowel disease in partnership with AbbVie.
- Therapeutic areas
- GastroenterologyEndocrinologyNeurologyImmunology
- Modalities
- pMHC nanomedicine drug candidates (Navacims)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
AbbVie (for PVT401)Resilience (for development and manufacturing)
Beyond the preview
Go deeper on Parvus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parvus Therapeutics.